Ziprasidone: Difference between revisions
ClaireLewis (talk | contribs) |
Elcatracho (talk | contribs) |
||
Line 48: | Line 48: | ||
==See Also== | ==See Also== | ||
*[[Antipsychotics]] | *[[Antipsychotics]] | ||
*[[Antipsychotic toxicity]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Psychiatry]] | [[Category:Psychiatry]] |
Latest revision as of 04:11, 7 March 2021
Administration
- Type: Atypical antipsychotic
- Dosage Forms:
- Routes of Administration: PO, IM
- Common Trade Names: Geodon
Adult Dosing
- Mania/psychosis: 40 to 80 mg PO BID
- Acute agitation: 10-20mg IM q2-4h, 40mg max daily
Pediatric Dosing
- Age 10-17: slowly titrate up to target dose 20-80mg BID
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic dosing: no adjustment
Contraindications
- Allergy to class/drug
- QT prolongation, concomitant administration of other QT prolonging medications
- Decompensated heart failure, recent MI
Adverse Reactions
Serious
- Prolonged QT, torsades de pointes, syncope
- Neuroleptic malignant syndrome, tardive dyskinesia, seizure
- Bone marrow depression
- Dysphagia
- Hyperglycemia, diabetes
- Priapism
Common
- Extrapyramidal disease, dystonia, tremor, akathisia
- Dizziness, asthenia, somnolence, anxiety
- Nausea/vomiting, diarrhea, constipation
- Weight gain
- Rash
- Visual changes
- URI
Pharmacology
- Half-life: 2-7h
- Metabolism: Hepatic: CYP3A4, and CYP1A2
- Excretion: Mostly fecal
Mechanism of Action
- D2 and 5HT2 antagonist. Also strong α-1 blocker, antihistamine-1.